Medication-Assisted Treatment (MAT) for opioid use disorder is the gold standard of care — endorsed by SAMHSA, NIDA, WHO, and every major medical organization. It reduces opioid use by 50–60%, cuts overdose mortality significantly, and improves retention in treatment. MAT is not "replacing one drug with another" — it's evidence-based medicine that stabilizes brain chemistry so that therapeutic work can happen.
The Three FDA-Approved Medications
| Medication | How It Works | Format | Key Considerations |
|---|---|---|---|
| Buprenorphine (Suboxone, Sublocade) | Partial opioid agonist — activates opioid receptors enough to reduce cravings and withdrawal without producing significant euphoria | Sublingual film/tablet (daily) or injection (monthly) | Can be prescribed by certified physicians in office settings. Most flexible option. |
| Naltrexone (Vivitrol) | Opioid antagonist — blocks opioid receptors entirely, preventing any effect from opioids | Monthly injection or daily oral tablet | Requires full detox before starting (7-14 days opioid-free). No abuse potential. |
| Methadone | Full opioid agonist — fully activates opioid receptors at a stable, controlled dose | Daily oral liquid at certified clinic | Most effective for severe dependence. Requires daily clinic visits initially. |
The Stigma Problem
Despite overwhelming evidence, MAT remains stigmatized — even within some treatment communities. People on buprenorphine are sometimes told they're "not really sober," excluded from 12-step meetings, or pressured to taper off medication prematurely. This stigma kills people. When someone stops MAT against medical advice due to social pressure, the risk of relapse and overdose spikes.
The analogy is simple: no one tells a diabetic that taking insulin means they're "not really managing their diabetes." No one tells someone with depression that antidepressants mean they're "not really doing the work." MAT stabilizes a medical condition so that the person can engage in therapy, rebuild relationships, return to work, and participate in recovery communities.
MAT in Colombian Treatment Programs
Colombian rehab facilities can initiate and stabilize patients on buprenorphine and naltrexone during residential treatment. The advantage of starting MAT in a residential setting is close medical supervision during medication initiation, ability to fine-tune dosing while the patient is monitored 24/7, and integration with behavioral therapy from day one. Before discharge, the treatment team coordinates a medication transition plan with a US-based prescriber, ensuring no gap in coverage.
Clinical guidelines recommend a minimum of 12 months, and many patients benefit from maintenance treatment for years or indefinitely. The decision to taper should be made collaboratively between patient and prescriber based on individual stability, support system strength, and risk factors — never based on arbitrary timelines or external pressure.
MAT-Informed Treatment in Colombia
Our network programs fully support medication-assisted treatment as part of comprehensive recovery. No stigma, no pressure to taper.
Learn More